Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo
出版年份 2023 全文链接
标题
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo
作者
关键词
-
出版物
KIDNEY INTERNATIONAL
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-02-03
DOI
10.1016/j.kint.2022.12.028
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
- (2022) Ian H. de Boer et al. DIABETES CARE
- Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
- (2021) Rune V. Overgaard et al. CLINICAL PHARMACOKINETICS
- Potential kidney protection with liraglutide and semaglutide – exploratory mediation analysis
- (2021) Johannes F. E. Mann et al. DIABETES OBESITY & METABOLISM
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
- (2020) Mansoor Husain et al. DIABETES OBESITY & METABOLISM
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
- (2020) John B. Buse et al. DIABETES CARE
- The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of LEADER and SUSTAIN 6 trials
- (2020) Lawrence A. Leiter et al. DIABETES OBESITY & METABOLISM
- The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
- (2020) Win L. Yin et al. Diabetes Therapy
- Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
- (2020) Subodh Verma et al. DIABETES OBESITY & METABOLISM
- Long-acting GLP-1RAs
- (2020) Ji Hyun Chun et al. JAAPA-Journal of the American Academy of Physician Assistants
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial
- (2020) Faiez Zannad et al. CIRCULATION
- Cardiovascular complications of chronic kidney disease: pioneering studies
- (2020) Tilman B. Drüeke et al. KIDNEY INTERNATIONAL
- Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients—the role of antidiabetic and antihypertensive medications
- (2020) Koichi Kitamura et al. HYPERTENSION RESEARCH
- Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
- (2020) Radica Z. Alicic et al. Nature Reviews Nephrology
- Duration of Diabetes and Cardiorenal Efficacy of Liraglutide and Semaglutide: A Post Hoc Analysis of the LEADER and SUSTAIN 6 Clinical Trials
- (2019) Subodh Verma et al. DIABETES OBESITY & METABOLISM
- GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
- (2019) Lesley A. Inker et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
- (2018) Charlotte Granhall et al. CLINICAL PHARMACOKINETICS
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
- (2016) Young-Sun Lee et al. MEDIATORS OF INFLAMMATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
- (2015) Merlin C. Thomas et al. Nature Reviews Nephrology
- Cardiovascular Complications of Diabetic Kidney Disease
- (2014) Ragnar Pálsson et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Diabetic Kidney Disease: A Report From an ADA Consensus Conference
- (2014) Katherine R. Tuttle et al. DIABETES CARE
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
- (2013) Hiroki Fujita et al. KIDNEY INTERNATIONAL
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started